You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》华检医疗(01931.HK)料「两票制」影响不大IVD行业推行有困难
阿思达克 06-28 18:00

中国体外诊断(IVD)产品分销商华检医疗(01931.HK)总经理林贤雅出席记者会时表示,「两票制」议题在医疗行业较热门,他解释「两票制」的意思是在价值链中限制最多发出两张发票,第一张发票由制造商发给分销商,第二张发票由分销商发给医院及医疗机构。

他指出早前收购的威士达为医疗保健公司希森美康的全国分销商并拥独家分销权,公司的中国法律顾问认为在相关情况下威士达可能被视作制造商,故希森美康向威士达的发票不会被计为第一张发票,所以预期「两票制」对集团影响不大。

首席营运官梁景新补充,公司分销IVD产品的大部分区域当局尚未将「两票制」应用於IVD产品行业,认为要在行业内推行相对较困难,留意到有一些省份想推动但亦未能成功。

主席兼行政总裁何鞠诚指出,未来公司发展有三个方向,一方面继续增加威士达的全国覆盖,另一方面要继续深耕上海市场,以及加强品牌的研发及投入。首席财务官周传波指出,公司部分募集资金亦将投入在自有品牌上,冀相关业务可助提升业绩。另外在产品定价方面,他指出公司会考虑来货价、市场接纳程度及竞争等,公司策略包括向下游传递、增加收入来源及改善产品组合等。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account